Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen VP-Licensing Scott Foraker: An Interview With “The Pink Sheet” DAILY (Part 1 of 2)

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche’s Mircera has not impacted Amgen’s aggressiveness on pursuing deals, Foraker says.

You may also be interested in...



Amgen Bundling Discounts Will Continue As J&J Case Heads To Trial

Court denies injunction sought by J&J to stop Amgen discounts based on amount of anemia products purchased.

Amgen Bundling Discounts Will Continue As J&J Case Heads To Trial

Court denies injunction sought by J&J to stop Amgen discounts based on amount of anemia products purchased.

Amgen VP-Licensing Scott Foraker: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

Foraker advises competitors to “watch out” for new Amgen initiatives in Asia “in the coming months.”

Related Content

Topics

UsernamePublicRestriction

Register

LL1135544

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel